Publikationen in Zusammenarbeit mit Forschern von Hospital General Universitario Gregorio Marañón (20)

2024

  1. How to use meropenem in pediatric patients undergoing CKRT? Integrated meropenem pharmacokinetic model for critically ill children

    Antimicrobial Agents and Chemotherapy, Vol. 68, Núm. 6

  2. The Effect of Polymorphisms and Other Biomarkers on Infliximab Exposure in Paediatric Inflammatory Bowel Disease: Development of a Population Pharmacokinetic Model

    Pediatric Drugs, Vol. 26, Núm. 3, pp. 331-346

2023

  1. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

2022

  1. Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study

    Intensive Care Medicine, Vol. 48, Núm. 7, pp. 850-864

  2. Population pharmacokinetics of piperacillin in critically ill children including those undergoing continuous kidney replacement therapy

    Clinical Microbiology and Infection, Vol. 28, Núm. 9, pp. 1287.e9-1287.e15

2021

  1. Selenium Derivatives as Promising Therapy for Chagas Disease: In Vitro and in Vivo Studies

    ACS Infectious Diseases, Vol. 7, Núm. 6, pp. 1727-1738

2020

  1. Estudio observacional de la toxicidad con diferentes formulaciones de docetaxel en pacientes con cáncer de mama

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 44, Núm. 5, pp. 192-197

  2. Finding the dose for ceftolozane-tazobactam in critically ill children with and without acute kidney injury

    Antibiotics, Vol. 9, Núm. 12, pp. 1-14

2019

  1. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients

    Leukemia Research, Vol. 76, pp. 1-10

2018

  1. Limitation of life support techniques at admission to the intensive care unit: A multicenter prospective cohort study

    Journal of Intensive Care, Vol. 6, Núm. 1

2017

  1. Prevención, diagnóstico y tratamiento de la obesidad. Posicionamiento de la Sociedad Española para el Estudio de la Obesidad de 2016

    Endocrinologia, Diabetes y Nutricion, Vol. 64, pp. 15-22

2016

  1. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome

    Critical Care, Vol. 20, Núm. 1

2014

  1. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: A bridge to individualized medicine

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 14, Núm. 4, pp. 305-318

2013

  1. The results of the pharmacosurveillance program in an oncological day hospital

    Atencion Farmaceutica, Vol. 15, Núm. 1, pp. 59-62

2011

  1. Literature review on the structure and operation of Pharmacy and Therapeutics Committees

    International Journal of Clinical Pharmacy, Vol. 33, Núm. 3, pp. 475-483

  2. Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter

    International Journal of Clinical Pharmacy

  3. Variabilidad en la actividad y los resultados de la evaluación de nuevos medicamentos por las comisiones de farmacia y terapéutica de los hospitales en España

    Farmacia Hospitalaria, Vol. 35, Núm. 6, pp. 305-314

2010

  1. Structure and procedures of the pharmacy and therapeutic committees in Spanish hospitals

    Pharmacy World and Science, Vol. 32, Núm. 6, pp. 767-775

2006

  1. Tegafur and 5-fluorouracil pelvic tissue concentrations in rectal cancer patients receiving preoperative chemoradiation

    Clinical and Translational Oncology, Vol. 8, Núm. 7, pp. 500-507

2002

  1. Implications of left bundle branch block in acute myocardial infarction treated with primary angioplasty

    American Journal of Cardiology, Vol. 90, Núm. 4, pp. 401-403